

Thyroid Transcription Factor, TTF-1 clone 8G7G3/1


Instructions for Use

Specification:

Anti-TTF-1 is useful in differentiating primary adenocarcinoma of the lung from metastatic carcinomas from the breast, mediastinal germ cell tumors and malignant mesothelioma. It can also be used to differentiate Small cell lung carcinoma from lymphoid infiltrates. Loss of TTF-1 expression in non-small cell lung carcinoma has been associated with aggressive behavior of such neoplasms.

Availability:

Catalog No.	Contents	Volume
ILM4311-C01	TTF-1	0,1 ml concentrate
ILM4311-C05	TTF-1	0,5 ml concentrate
ILM4311-C1	TTF-1	1,0 ml concentrate



Intended use: For Research Use Only

Reactivity: Human, Mouse and Rat

Clone: 8G7G3/1

Species of origin: Mouse

Isotype: IgG1, kappa

Control Tissue: Adenocarcinoma of lung, normal lung, thyroid

Staining: Nuclear

Immunogen: Rat full length TTF-1 recombinant protein

Presentation: Bioreactor Concentrate with 0.05% Azide, the ready-to-use antibody is diluted in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Application and suggested dilutions:

Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

- Immunohistochemical staining of cryostat tissue sections (dilution up to 1:50-1:100)
- Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution up to 1:50-1:100)
- Western blotting

The optimal dilution for a specific application should be determined by the investigator.

- Ready-to-use: Apply the prediluted antibody and incubate for 30-60 minutes at room temperature.

Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial. For long term storage, aliquot and freeze.

References:

- 1) Bejarano, P.A. et al. Mod Pathol 1996 Apr;9(4): 445-52
- 2) Di Loreto C, et al. Cancer Lett 1998 Feb13;124(1):73-8
- 3) Di Loreto C. et al, J Clin Pathol 1997 Jan;50(1):30-2
- 4) Holzinger A et al. Hybridoma. 1996 Feb;15(1):49-53
- 5) Agoff SN et al. Mod Pathol. 2000 Mar;13(3):238-42
- 6) Katoh R et al. Mod Pathol. 2000 May;13(5):570-6
- 7) Jang KY et al. Anal Quant Cytol Histol. 2001 Dec;23(6):400-4
- 8) Srodon M, Westra WH. Hum Pathol. 2002 Jun;33(6):642-5
- 9) Abutaily AS et al. J Clin Pathol. 2002 Sep;55(9):662-8
- 10) Bejarano PA, Mousavi F. Arch Pathol Lab Med. 2003 Feb;127(2):193-5
- 11) Saad RS et al. Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):107-12
- 12) Tan D et al. Hum Pathol. 2003 Jun;34(6):597-604